Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$0.19
-5.0%
$0.19
$0.00
$0.25
$55.63M1.9199,938 shs5,750 shs
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
$0.00
$0.00
$0.00
$0.01
N/AN/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
$0.08
-11.3%
$0.08
$0.01
$0.21
$9.97M0.0614,703 shs375 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.00%+3.79%-2.44%+29.12%+24.92%
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
-11.26%-11.26%+8.24%-24.45%-42.90%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$0.19
-5.0%
$0.19
$0.00
$0.25
$55.63M1.9199,938 shs5,750 shs
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
$0.00
$0.00
$0.00
$0.01
N/AN/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
$0.08
-11.3%
$0.08
$0.01
$0.21
$9.97M0.0614,703 shs375 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.00%+3.79%-2.44%+29.12%+24.92%
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
-11.26%-11.26%+8.24%-24.45%-42.90%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.00
N/AN/AN/A
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
0.00
N/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
0.00
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
NSPX
Inspyr Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$33.12M1.68$0.01 per share17.28$0.01 per share19.00
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/AN/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
N/AN/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$3.25MN/A0.00N/A7.93%72.31%41.28%11/13/2025 (Estimated)
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
-$1.89MN/A0.00N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/A
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.01
0.91
0.67
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
N/AN/AN/A
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
N/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
CompanyEmployeesShares OutstandingFree FloatOptionable
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
3292.79 million221.02 millionNot Optionable
Immune Pharmaceuticals Inc. stock logo
IMNPQ
Immune Pharmaceuticals
7N/AN/ANot Optionable
EOM Pharmaceutical Holdings, Inc. stock logo
IMUC
EOM Pharmaceutical
3126.50 million122.35 millionNot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable

Media Sentiment Over Time

Earth Science Tech stock logo

Earth Science Tech OTCMKTS:ETST

$0.19 -0.01 (-5.00%)
As of 11:08 AM Eastern

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

Immune Pharmaceuticals stock logo

Immune Pharmaceuticals OTCMKTS:IMNPQ

$0.0010 0.00 (0.00%)
As of 08/17/2022

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.

EOM Pharmaceutical stock logo

EOM Pharmaceutical OTCMKTS:IMUC

$0.08 -0.01 (-11.26%)
As of 09/15/2025 11:15 AM Eastern

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.